Bio-Rad Announces Completion of Exchange Offer HERCULES, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Bio-Rad Laboratories, Inc. (Amex: BIO; BIO.B), a multinational manufacturer and distributor of life science research products and clinical diagnostics, announced today that it has completed its offer to exchange $225.0 million aggregate principal amount of its 7.50% Senior Subordinated Notes due 2013 which have been registered under the Securities Act of 1933, as amended (the "Exchange Notes") for any and all of its outstanding 7.50% Senior Subordinated Notes due 2013 which were issued in a private placement (the "Private Notes"). All of the $225.0 million aggregate principal amount of the Private Notes were tendered and received prior to expiration of the Exchange. This announcement is not an offer to exchange, or a solicitation of an offer to exchange, with respect to the Private Notes. The Exchange Offer was made solely by the prospectus dated October 1, 2003. DATASOURCE: Bio-Rad Laboratories, Inc. CONTACT: Christine Tsingos, Vice President and Chief Financial Officer, or Ron Hutton, Treasurer, +1-510-724-7000, or , both of Bio-Rad Laboratories, Inc. Web site: http://www.bio-rad.com/

Copyright